Over the past three decades, SHL Group has partnered with the majority of the world’s top 25 leading pharmaceutical and biotech companies to bring more than 30 autoinjector-drug combination products to market. Autoinjectors represent one of the fastest growing segments in drug self-administration, supporting a range of chronic conditions including diabetes, rheumatoid arthritis, multiple sclerosis, migraine and cardiovascular disease.

The increasing prevalence of chronic conditions has amplified the demand for new medication options. As a result, the biopharmaceutical market is growing at double the rate of traditional small-molecule pharma. To cater for the growing pipeline of these macromolecule biologics and biosimilars, SHL continues to invest heavily in the development of drug delivery devices, covering a wide range in both volume and viscosity (Figure 1).

Here, Ramin Rafiei, PhD, Director of Technology at SHL Group, argues that solely relying on the clinical efficacy of medications is no longer adequate for improving patient clinical outcomes. Connected therapeutics – the augmentation of drugs through sensors and connectivity – are now a clinical source for real-world data and provide an opportunity to bridge the efficacy-to-effectiveness gap. This next frontier in drug delivery, powered by connected therapeutics, will be data-driven, personalised, outcomes-based and accessible.

“Chronic conditions place healthcare systems worldwide under significant stress.”

Figure 1: SHL Group develops a range of disposable and re-usable injectors that can accommodate high volumes and high viscosities and can be enhanced through digital implementations.
Chronic conditions place healthcare systems worldwide under significant stress. For example, in the US, the number of people with diabetes has grown 20-fold over the past three decades, while costs on a per-patient level have also increased by 7.5% annually. Unlike any other industry, where cost goes down as products and services scale, there is both an increasing prevalence of chronic conditions and increasing cost for managing each patient.

A major reason for this trend is the efficacy-to-effectiveness (E2E) gap. Figure 2 illustrates the E2E gap for Type 2 diabetes. The top line shows the 26 new Type 2 diabetes medications approved between 1999 and 2014, each with proven clinical efficacy. The bottom line shows the percentage of the population with Type 2 diabetes which has the condition under control, specifically defined as a haemoglobin A1c level below 7%. Diabetes patients typically monitor their glucose levels through a mechanism known as the A1c test, which is the average blood sugar level for the past two to three months. A1c levels are an indication of treatment efficacy, therefore, patients are tasked to keep their A1c levels as close as possible to their target percentages, which are typically around 6-7%. While between 1999 and 2003 new therapies, such as Sanofi’s Lantus (insulin glargine) proved effective in helping patients reach optimum A1c levels, this trend failed to continue beyond 2003.

The E2E gap refers to the separation between the clinical efficacy of new drugs as determined by randomised controlled trials and their real-world effectiveness. Given the intense frequency of follow-up and support for participants, clinical trials take place in highly controlled environments whereas, in the real world, the patient needs to self-manage their treatment. As a result, solely relying on the clinical efficacy of new medications is not the solution to chronic disease management; rather, we need to find ways of helping patients manage existing conditions – what we refer to as the self-management gap.

Bridging this gap demands a systemic focus on medication adherence as typically 50% of people with chronic conditions fail to take their medications as prescribed. The consequences of poor adherence to long-term therapies are poor health outcomes and increased healthcare costs. Non-adherence to medication, however, is a complex and multidimensional healthcare problem and stems from the diversity of patient behaviours and barriers. The fact that non-adherence remains a major problem after decades of research shows just how difficult it can be to identify and address effectively. It has been shown that non-adherent patients cost the healthcare system significantly more in medical costs across all chronic disease states. Today, the measured adherence level of 50% or lower across most chronic conditions is typically based on prescription refill claims data. It has also been shown that true adherence or dose-level adherence is 15-30% lower when measured with connected drug delivery devices. This means the reported avoidable medical costs associated with medication non-adherence are actually underestimations since patients considered adherent based on prescription refill claims data might not be taking the drug as prescribed.

"Once we are able to measure adherence, we can address it through interventions, support and resources.”

Figure 2: An illustration of the efficacy-to-effectiveness gap for Type 2 diabetes.
BRIDGING THE GAP

Connected therapeutics – the augmentation of drugs through sensors and connectivity – generate real-world data. This data provides a digital representation of the patient’s true self-care behaviours and health outcomes outside the clinic. Real-world data from connected therapeutics also complements other traditional sources of clinical data, including electronic medical records as well as pharmacy and medical claims. The fusion of these data sets can now provide an unparalleled view of patient behaviours not formerly possible.

Drug delivery devices, which passively and objectively measure adherence at the point the patient is interacting with their medication, provide the greatest opportunity to bridge the E2E gap. Once we are able to measure adherence, we can address it through interventions, support and resources. If we are able to improve adherence, then we will also indirectly improve both clinical and financial outcomes. Today, Moore’s law, the alignment of incentives among stakeholders, and improved regulatory pathways, are converging to pave the way for connected therapeutics.

ACCELERATION BY TECHNOLOGY

In the biopharmaceutical industry, Eroom’s law (Moore spelt backwards) refers to the exponentially increasing cost of bringing new drugs to market.20 On the other hand, Moore’s law has transformed computing through exponentially decreased costs. As technology continues to get smaller, lighter, more efficient and easier to use, sensors and computers are making their way into drug delivery devices. Here, injectable therapies are still in their infancy when compared with connected respiratory and oral therapies. However, studies across the three connected therapeutic categories have consistently demonstrated improved patient adherence and overall health outcomes.21-24 Therefore, while bringing drugs to market with proven clinical efficacy is an increasingly costly endeavour based on Eroom’s law, the application of Moore’s law to drug delivery has the potential to improve the return on investment by bridging the E2E gap.

ACCELERATION BY ALIGNMENT

The second and most important trend driving the adoption of connectivity in healthcare is the alignment of incentives among stakeholders around quality and outcomes. Pharmaceutical companies are increasingly taking on risks through value-based contracts as a way to get more coverage and improve their formulary positions.25-26 Under these contracts, the price that insurers pay for drugs is tied to either the clinical outcome or an adherence threshold. Interestingly, adherence is a common factor in all the contracts, either as a qualifying event (i.e. only patients who refill their prescription on time are included in the contract) or as an outcome (i.e. the pharmaceutical company is paid less for patients who are non-adherent). Connected drug delivery devices, which generate dose-level adherence data, will become an important tool for pharmaceutical companies in these value-based contracts. Dose-level data will limit exposure when adherence is a qualifier for the contract by identifying patients who refilled their prescription but are not using the medication properly.

The US 21st Century Cures Act of 2016 (Cures Act), signed into law on December 13, 2016, is designed to accelerate the discovery, development and delivery of new cures and treatments for disease.27 The Cures Act has made it possible for pharmaceutical companies to expand their label into new conditions using real-world data instead of running additional clinical trials for each condition. Since we know real-world adherence is low, connectivity in drug delivery devices will be a necessary tool that allows pharmaceutical companies to generate the evidence from cohorts of patients who are using the medication as prescribed.

Healthcare providers are another important stakeholder driving the adoption of connectivity. Historically, providers have not been on board with remote monitoring primarily due to the absence of a financial incentive. With the 2019 US Proposed Rule, remote care enabled by connected devices has moved to the forefront and providers
“The next frontier in drug delivery, powered by connected therapeutics, will be data driven, personalised, outcomes based and accessible.”

are being reimbursed for high-quality, high-impact care.24 New Medicare codes now reimburse physicians for remote patient monitoring devices and services. Given there are over 35 million Medicare patients in the US and 80% have multiple comorbidities, this presents a significant market catalyst for the adoption of connectivity.24

ACCELERATION BY REGULATION

The US FDA has been proactive in improving the regulatory pathway for managing the data generated by software and connected drug delivery devices. The FDA Software Precertification Program, currently in pilot mode, effectively certifies the organisation developing the digital healthcare product rather than looking primarily at the product itself. This approach stems from the nature of software itself, which undergoes rapid, continuous and iterative improvements. This, according to the FDA, will “provide more streamlined and efficient regulatory oversight of software-based medical devices developed by manufacturers who have demonstrated a robust culture of quality and organisational excellence.”29

The most recent development is the FDA’s artificial intelligence (AI) discussion paper.30 Here AI refers to software, which can change its mind and improve its learning or decision making based on new data. While there are already a number of so-called “locked algorithms” approved by the FDA and used in the measurement of stroke risk or detection of diabetic retinopathy, this recent paper aims to tailor to AI’s adaptive nature. Such efforts by the FDA, which aim to simplify and streamline approvals, are expected to accelerate the adoption of connectivity.

CONNECTIVITY TO CARE

When we look at the evolution of the patient experience in drug delivery, we see that patients have traditionally been tethered to healthcare professionals, typically needing to visit a clinic for the administration of their treatment (Figure 3). As autoinjectors set a new standard in drug delivery, patients were empowered to manage their treatments, and do so in a safe and convenient manner. With the adoption of connectivity, drug delivery devices are becoming an important source of real-world data which is now passively measuring adherence. The true value of this data lies in its ability to improve health outcomes through the personalisation of interventions and care delivery. This next frontier in drug delivery, powered by connected therapeutics, will be data driven, personalised, outcomes based and accessible. Only then will connected therapeutics reach their full value.

ABOUT THE COMPANY

SHL Group is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. It also offers core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, SHL’s experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. This includes advanced re-usable and disposable injectors that can accommodate high volumes and high viscosities and can be enhanced through digital implementations.

REFERENCES

5. “FDA Approved Drugs for Endocrinology”. CenterWatch.
20. Scannell J et al, “Diagnosing the
29. “Digital Health Software Precertification (Pre-Cert) Program”. US FDA.
30. “Artificial Intelligence and Machine Learning in Software as a Medical Device”. US FDA.

ABOUT THE AUTHOR

Ramin Rafiei, PhD is Director of Technology at SHL Group, leading the organisation’s efforts in digital healthcare. His focus is the intersection of connected therapeutics, software and personalised care delivery with the aim of bridging the efficacy-to-effectiveness gap. Over the past two decades, Dr Rafiei has been leading high-stake multidisciplinary scientific and business initiatives globally across established industries such as aerospace and nuclear, as well as next-generation industries such as photonics, autonomous mobility and digital healthcare. Dr Rafiei is a healthcare investor, a healthtech advisor and a published author who holds a PhD in experimental nuclear physics from The Australian National University (Canberra, Australia).

The Injectables Summit returns to San Diego - September 24 – 26, 2019

9TH EDITION
INJECTABLES
SUMMIT 2019

Be Part of the Device Engineering Evolution: From Smart Injectors to Delivering Quality Patient Care

Confirmed Partners

To register for the 2019 meeting, please visit www.pfs-injectables.com
@info@hansonwade.com ☎+1 212 537 5898
We Bring Innovation to Life

Connecting people through digital solutions

Connecting world-class hardware with active partnerships, SHL offers a full range of connected drug delivery solutions for next-generation healthcare.

Learn more at the 2019 PDA Universe of Pre-filled Syringes & Injection Devices

Oct 22-23 | Gothenburg, Sweden | Booth 45-47